<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39318314</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1000-0607</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Zhen ci yan jiu = Acupuncture research</Title><ISOAbbreviation>Zhen Ci Yan Jiu</ISOAbbreviation></Journal><ArticleTitle>Observation of clinical efficacy of acupuncture combined with bloodletting therapy and Qingwen Xiere decoction in mild to moderate COVID-19 patients.</ArticleTitle><Pagination><StartPage>845</StartPage><EndPage>850</EndPage><MedlinePgn>845-850</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.13702/j.1000-0607.20230316</ELocationID><ELocationID EIdType="pii" ValidYN="Y">1000-0607(2024)08-0845-06</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the clinical efficacy and safety of acupuncture combined with bloodletting therapy and Qingwen Xiere decoction in mild to moderate COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 100 mild to moderate COVID-19 patients collected from December 2022 to February 2023 were randomly divided into control and observation groups, with 50 patients in each group. Patients in the control group received oral Qingwen Xiere decoction for 6 days. The observation group received acupuncture combined with bloodletting therapy in addition to oral Qingwen Xiere decoction, with the acupuncture (at Kongzui ［LU6］, Hegu ［LI4］, Quchi ［LI11］, Feishu ［BL13］, Zhongwan ［CV12］, Qihai ［CV6］, Yinlingquan ［SP9］) administered 30 min each day for 6 days, and bloodletting (at Shaoshang ［LU11］, Shangyang ［LI1］, Dazhui ［GV14］) administered every other day for 3 times. Traditional Chinese medicine syndrome scores and pulmonary CT scores were recorded before and after treatment. Serum contents of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured using ELISA. Anxiety and depression degree were assessed using the Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA). Safety of the treatments was evaluated in both groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with before treatment, after treatment, the control group showed improvement in fever, dry cough, sore throat, and total traditional Chinese medicine syndrome scores (<i>P</i>&lt;0.01), but no significant improvement in muscle pain or fatigue；the observation group showed significant improvement in total traditional Chinese medicine syndrome and individual symptoms scores (<i>P</i>&lt;0.01)；both groups demonstrated reductions in pulmonary CT scores, HAMA score, HAMD score and serum contents of CRP and IL-6 (<i>P</i>&lt;0.01)；serum TNF-α content significantly decreased in the observation group (<i>P</i>&lt;0.01). All outcome measures were superior in the observation group to the control group (<i>P</i>&lt;0.01, <i>P</i>&lt;0.05). No adverse reactions were reported in either group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Acupuncture combined with bloodletting therapy and oral Qingwen Xiere decoction effectively improves clinical symptoms, alleviates pulmonary inflammatory injury, reduces inflammatory cytokine contents, and mitigates anxiety and depression in mild to moderate COVID-19 patients, and without adverse effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Tian-Xin</ForeName><Initials>TX</Initials><AffiliationInfo><Affiliation>The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bao-Guo</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qi-Qi</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Anhui University of Chinese Medicine, Hefei 230000.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shou-Liang</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, China. 316029622@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Anhui University of Chinese Medicine, Hefei 230000.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><VernacularTitle>针刺联合刺血及清瘟泄热汤对新型冠状病毒感染轻中型患者临床疗效观察.</VernacularTitle></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhen Ci Yan Jiu</MedlineTA><NlmUniqueID>8507710</NlmUniqueID><ISSNLinking>1000-0607</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015670" MajorTopicYN="Y">Acupuncture Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001815" MajorTopicYN="Y">Bloodletting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015669" MajorTopicYN="N">Acupuncture Points</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的</b>: 观察针刺联合刺血及中药清瘟泄热汤对轻中型新型冠状病毒（COVID-19）感染患者的临床疗效及安全性。<b>方法</b>: 将2022年12月至2023年2月收治的100例COVID-19轻中型患者，按照1∶1比例随机分为对照组和观察组，每组50例。对照组予以中药清瘟泄热汤口服，连续服用6 d。观察组在对照组基础上加用针刺联合刺血治疗，针刺每日1次，每次30 min，连续治疗6 d；刺血隔日1次，治疗3次。治疗前和治疗结束当日，记录患者的中医证候评分和肺部CT评分，采用ELISA法检测患者血清C反应蛋白（CRP）、白细胞介素6（IL-6）及肿瘤坏死因子α（TNF-α）水平，采用汉密尔顿抑郁量表（HAMD）及汉密尔顿焦虑量表（HAMA）评价患者抑郁焦虑水平，并评定两组治疗的安全性。<b>结果</b>: 与本组治疗前比较，治疗后对照组患者在发热、干咳、咽痛和中医证候评分总分方面有所改善（<i>P</i>&lt;0.01），而肌肉酸痛、乏力未见明显好转；观察组患者中医症候评分总分和各项证候均显著改善（<i>P</i>&lt;0.01）；两组患者肺部CT评分、HAMA和HAMD评分、血清CRP和IL-6含量均降低（<i>P</i>&lt;0.01），观察组患者血清TNF-α含量降低（<i>P</i>&lt;0.01）。治疗后观察组各项指标的改善均优于对照组（<i>P</i>&lt;0.01，<i>P</i>&lt;0.05）。两组患者均未出现不良反应。<b>结论</b>: 针刺联合刺血及口服清瘟泄热汤治疗轻中型COVID-19感染，可明显改善患者临床症状，缓解肺部炎性损伤，降低炎性因子含量，减轻焦虑和抑郁情绪，且无不良反应发生。.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acupuncture</Keyword><Keyword MajorTopicYN="N">Bloodletting</Keyword><Keyword MajorTopicYN="N">COVID-19 infection</Keyword><Keyword MajorTopicYN="N">Qingwen Xiere decoction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39318314</ArticleId><ArticleId IdType="doi">10.13702/j.1000-0607.20230316</ArticleId><ArticleId IdType="pii">1000-0607(2024)08-0845-06</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>LIU L H ， IKETANI S ， GUO Y C ， et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 ［J］. Nature ， 2022 ， 602 （ 7898 ）： 676- 681.</Citation></Reference><Reference><Citation>汤薪玉 ， 黄伟强 ， 包剑锋. 从Delta到Omicron——中医药对新型冠状病毒肺炎的诊治思路初探 ［J］. 浙江中医药大学学报 ， 2022 ， 46 （ 11 ）： 1211- 1218.</Citation></Reference><Reference><Citation>中华人民共和国国家卫生健康委员会办公厅 ， 中华人民共和国国家中医药管理局综合司. 新型冠状病毒感染诊疗方案（试行第十版） ［J］. 中国医药 ， 2023 ， 18 （ 2 ）： 161- 166.</Citation></Reference><Reference><Citation>中国针灸学会. 新型冠状病毒肺炎针灸干预的指导意见（第二版） ［J］. 中国针灸 ， 2020 ， 40 （ 5 ）： 462- 463.</Citation></Reference><Reference><Citation>詹志来 ， 刘佳 ， 杨伟 ， 等. 基于病例分析的中医药治疗新型冠状病毒肺炎疗效评价标准的探索研究 ［J］. 中医杂志 ， 2020 ， 61 （ 12 ）： 1013- 1023.</Citation></Reference><Reference><Citation>占丰富 ， 曾惠清 ， 黄茂宏 ， 等. 年龄和CT评分预测新冠肺炎住院患者的死亡风险： 基于A-DROP评分 ［J］. 中国医药导刊 ， 2022 ， 24 （ 4 ）： 366- 374.</Citation></Reference><Reference><Citation>侍成栋 ， 潘永良. 汉密尔顿抑郁及焦虑量表与正性负性情绪量表的相关性研究 ［J］. 全科护理 ， 2019 ， 17 （ 2 ）： 140- 142.</Citation></Reference><Reference><Citation>PULLIAM J R C ， VAN SCHALKWYK C ， GOVENDER N ， et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa ［J］. Science ， 2022 ， 376 （ 6593 ）： eabn4947.</Citation></Reference><Reference><Citation>郭雨怡 ， 王福民 ， 滕雨可 ， 等. 新冠肺炎疫情防治背景下针灸治疗肺系疾病的选穴规律分析 ［J］. 世界科学技术-中医药现代化 ， 2020 ， 22 （ 10 ）： 3485- 3492.</Citation></Reference><Reference><Citation>时宜蓉 ， 乔赟. 孔最、鱼际穴平喘作用及机制研究进展 ［J］. 广西中医药大学学报 ， 2020 ， 23 （ 4 ）： 60- 63.</Citation></Reference><Reference><Citation>张林 ， 李世兵 ， 周晓英 ， 等. 针刺曲池、合谷治疗外感发热（风热证）的临床疗效研究 ［J］. 针灸临床杂志 ， 2015 ， 31 （ 1 ）： 4- 7.</Citation></Reference><Reference><Citation>李露露 ， 宋圆英 ， 胡馨予 ， 等. 中医药促进新型冠状病毒肺炎感染后患者康复的临床方案初探 ［J］. 中药药理与临床 ， 2021 ， 37 （ 1 ）： 2- 6.</Citation></Reference><Reference><Citation>熊坚 ， 黄慧 ， 张颖春 ， 等. 基于R语言数据挖掘技术分析针灸治疗咳嗽变异性哮喘的取穴规律 ［J］. 护理研究 ， 2023 ， 37 （ 4 ）： 671- 677.</Citation></Reference><Reference><Citation>李佩泽 ， 梁家彬 ， 郑焕驰 ， 等. 放血疗法治疗急性扁桃体炎的Meta分析 ［J］. 中医药导报 ， 2020 ， 26 （ 11 ）： 138- 143， 149.</Citation></Reference><Reference><Citation>孟家乐 ， 袁思成 ， 王毅军 ， 等. 井穴和耳尖放血治疗新型冠状病毒感染无症状及轻症外感风热证咽痛患者回顾性队列研究 ［J］. 中国中西医结合杂志 ， 2023 ， 43 （ 4 ）： 410- 414.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>